The National Institute for Health and Care Excellence (NICE) have published new or updated guidance for the month of November 2021. This month there are four guidelines and one COVID-19 rapid guideline that impact upon primary care.
The Heart valve disease presenting in adults: investigation and management guideline has been published. It covers investigation and management of heart valve disease presenting in adults. It aims to improve quality of life and survival for people with heart valve disease through timely diagnosis and appropriate intervention.
The Acute heart failure: diagnosis and management guideline has been updated. Recommendations on valvular surgery and percutaneous intervention have been withdrawn and replaced by the new guideline above.
The Type 2 diabetes in adults: management guideline has been updated. The update reviewed the evidence and made new recommendations for SGLT2 inhibitors for adults with type 2 diabetes and chronic kidney disease.
The Chronic kidney disease: assessment and management guideline has been updated. The guidance on SGLT2 inhibitors for adults with type 2 diabetes and chronic kidney disease has been updated and links to the Type 2 diabetes in adults guideline.
The COVID-19 rapid guideline: managing the long-term effects of COVID-19 guideline has been updated. The update makes new recommendations and updates existing recommendations in several areas including identification, planning care, multidisciplinary rehabilitation and follow up. The list of common symptoms was also updated, emphasising that these may be different for children.
Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.
|« Drug Safety Update - November 2021|